Q0517 HCPCS Level II code: Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-days
CMS terminated Q0517: its last date of service was Dec 31, 2024. It stays here for looking up older claims; newer services need a current code.
Official description
Q0517Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-days
Short description: Supply fee hiv prep oral 60
HCPCS · United States
Notes for Q0517
As CMS prints them, with any note Q0517 takes from the headings above it.
Note
- CMS processing note 0129: MMA section 303(e).
Medicare details
The indicators CMS publishes with Q0517 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- DMEPOS fee schedule – Carrier priced (e.g., not otherwise classified, individual determination, carrier discretion, gap-filled amounts)
- Type of service
- Other medical items or services
- BETOS category
- Other drugs
- Coverage statute
- 1861(ddd)
- Added
- Jan 2, 2024
- Terminated after
- Dec 31, 2024
Where Q0517 sits
- 1Q codesTemporary codes
- 2Terminated Q0517Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-days
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code Q0517 still valid?
No. CMS terminated Q0517; its last date of service was Dec 31, 2024. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover Q0517?
CMS lists Q0517’s Medicare coverage as “Special coverage instructions apply” and its pricing as “DMEPOS fee schedule – Carrier priced (e.g., not otherwise classified, individual determination, carrier discretion, gap-filled amounts)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q0517
All Q codesQ0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodQ0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day periodQ0513Pharmacy dispensing fee for inhalation drug(s); per 30 daysQ0514Pharmacy dispensing fee for inhalation drug(s); per 90 daysQ0515Injection, sermorelin acetate, 1 microgramQ0516Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 30-daysQ0518Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 90-daysQ0519Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 30-daysQ0520Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 60-daysQ0521Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescriptionQ1004New technology intraocular lens category 4 as defined in federal register noticeQ1005New technology intraocular lens category 5 as defined in federal register notice